Twist Bioscience Corp TWST
At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us.
We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. We have miniaturized traditional chemical DNA synthesis reactions to write over 1,000,000 pieces of DNA (oligonucleotides) up to 500 bases through direct synthesis on each silicon chip, approximately the size of a large mobile phone, reducing by 99.8% the amount of chemicals we estimate would be used per gene as compared to plate-based synthesis. We have combined our silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost and quicker than our competitors.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $376.6M | $313.0M | $245.1M | $203.6M | $132.3M | $90.1M | $54.4M | $25.4M | $10.8M | — |
| Cost of revenue | $185.6M | $179.6M | $155.4M | $119.3M | $80.6M | $61.4M | $47.4M | $32.2M | $24.0M | — |
| Gross profit | $191.0M | $133.3M | $89.7M | $84.2M | $51.7M | $28.7M | $7.0M | -$6.8M | -$13.3M | — |
| R&D | $80.3M | $90.9M | $106.9M | $120.3M | $69.1M | $43.0M | $35.7M | $20.3M | $19.2M | — |
| SG&A | $247.0M | $218.4M | $189.7M | $212.9M | $135.9M | $103.3M | $80.1M | $43.5M | $26.1M | — |
| Total operating expenses | $512.8M | $533.8M | $462.3M | $438.3M | $285.1M | $230.2M | $163.2M | $96.0M | $69.2M | — |
| Operating income | -$136.3M | -$220.8M | -$217.2M | -$234.8M | -$152.7M | -$140.1M | -$108.8M | -$70.6M | -$58.5M | — |
| Interest expense | — | $29.0K | $5.0K | $80.0K | $367.0K | $787.0K | $1.3M | $1.3M | $905.0K | — |
| Pre-tax income | -$77.0M | -$208.2M | -$203.5M | -$228.3M | -$154.0M | -$139.5M | -$107.4M | -$71.0M | -$59.0M | — |
| Income tax | $719.0K | $560.0K | $1.2M | $10.4M | $1.9M | $382.0K | $292.0K | $242.0K | $280.0K | — |
| Net income | -$77.7M | -$208.7M | -$204.6M | -$217.9M | -$152.1M | -$139.9M | -$107.7M | -$71.2M | -$59.3M | — |
| EPS, basic | -1.30 | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | — | — | — | — |
| EPS, diluted | -1.30 | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -25.51 | -24.49 | — |
| Shares, diluted (wtd. avg.) | $59.8M | $58.0M | $56.9M | $53.9M | $48.3M | $39.2M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $183.0M | $226.3M | $289.3M | $380.3M | $467.4M | $94.2M | $47.4M | $81.5M | $31.6M | $29.1M |
| Short-term investments | $49.4M | $50.1M | $49.9M | $126.3M | $12.0M | $196.3M | $91.4M | — | — | — |
| Receivables | $57.0M | $34.9M | $44.1M | $40.3M | $28.5M | $26.4M | $12.1M | $5.4M | — | — |
| Inventory | $28.3M | $24.1M | $32.1M | $39.3M | $31.8M | $12.3M | $7.3M | $6.0M | — | — |
| Total current assets | $333.0M | $346.8M | $424.3M | $596.5M | $546.5M | $334.9M | $160.1M | $95.7M | — | — |
| Property, plant and equipment | $102.3M | $102.5M | $131.8M | $139.4M | $44.1M | $25.5M | $20.8M | $12.3M | — | — |
| Goodwill | $82.2M | $85.8M | $85.8M | $85.8M | $22.4M | $1.1M | $1.1M | $1.1M | — | — |
| Other intangibles | $13.4M | $14.5M | $54.5M | $59.7M | $18.3M | $307.0K | $508.0K | $712.0K | — | — |
| Total assets | $641.9M | $614.3M | $776.4M | $961.4M | $702.1M | $398.9M | $187.0M | $115.8M | — | — |
| Accounts payable | $11.1M | $1.6M | $14.1M | $20.1M | $14.9M | $4.8M | $9.8M | $7.5M | — | — |
| Short-term debt | — | — | — | $0 | $1.6M | $3.3M | $3.3M | $2.5M | — | — |
| Total current liabilities | $91.4M | $71.0M | $73.3M | $90.7M | $63.1M | $36.0M | $30.4M | $18.5M | — | — |
| Long-term debt | — | — | — | — | — | $1.4M | $4.4M | $7.2M | — | — |
| Total liabilities | $168.9M | $141.6M | $153.0M | $172.0M | $121.3M | $62.6M | $34.9M | $26.7M | — | — |
| Retained earnings | -$1.32B | -$1.24B | -$1.03B | -$828.4M | -$610.6M | -$458.5M | -$318.5M | -$210.9M | — | — |
| Total equity | $473.0M | $472.7M | $623.4M | $789.4M | $580.8M | $336.3M | $152.1M | -$201.4M | -$133.4M | -$76.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$47.6M | -$64.1M | -$142.5M | -$124.4M | -$112.2M | -$142.3M | -$87.9M | -$66.2M | -$51.3M | — |
| Depreciation and amortisation | $24.9M | $31.4M | $29.3M | $16.5M | $9.8M | $6.7M | $6.1M | $5.7M | $5.0M | — |
| Stock-based compensation | $64.5M | $50.9M | $30.3M | $79.7M | $37.0M | $17.1M | $11.2M | $3.0M | $1.9M | — |
| Capital expenditure | $28.0M | $5.1M | $27.8M | $101.9M | $27.1M | $9.9M | $14.8M | $3.7M | $6.6M | — |
| Investing cash flow | -$24.8M | -$3.1M | $50.6M | -$232.9M | $156.2M | -$114.7M | -$104.8M | $27.3M | -$10.0M | — |
| Financing cash flow | $28.5M | $6.9M | $911.0K | $270.5M | $329.2M | $303.7M | $158.6M | $88.8M | $63.8M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001581280-25-000025.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |